Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC

Trial Profile

Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs GPC3-CAR-T (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 06 Jun 2017 Preliminary safety and efficacy results, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 25 Apr 2017 Status changed from recruiting to discontinued for reason not related to safety, efficacy, feasibility, or funding issues.
    • 04 Apr 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top